strategic pivot
Editas Medicine Reboots With Cholesterol Gene Therapy (EDIT-401) as Lead Asset
Editas Medicine; EDIT-401; gene therapy; hyperlipidaemia; LDL cholesterol; LDLR gene; in vivo gene editing; strategic pivot; clinical development
Coherus BioSciences Completes Strategic Shift with $483M Sale of Last Biosimilar Asset
Coherus BioSciences, biosimilars, strategic pivot, pharmaceutical industry, biotechnology
IGM Biosciences Undergoes Strategic Pivot to Autoimmune Diseases, Overhauls Leadership and Reduces Workforce
IGM Biosciences, autoimmune diseases, strategic pivot, T cell-engaging IgM antibodies, leadership changes, workforce reduction, imvotamab, IGM-2644
Teladoc Posts $838M Loss in Q2, Announces Strategic Pivot for BetterHelp
Teladoc, BetterHelp, Q2 loss, strategic pivot, telehealth, virtual healthcare